Johan Emilsson, CEO of Sprint Biosciences, was featured in an interview with BiotechTV during the Swiss Nordic Bio 2026 investor conference. The discussion focused on how the company uses fragment-based drug discovery to identify and develop new small-molecule drug candidates.

Watch the interview here: Biotech TV